

Special Issue

Surgical Infections and Sepsis: Epidemiology, Prevention and Antimicrobial Chemotherapy

Message from the Guest Editors

Surgical site infections (SSI) are infections resulting from a surgical procedure and represent one of the main types of healthcare-related infections. SSIs are classified according to the planes affected: superficial incisional SSI, deep incisional SSI, and organ/cavity SSI. According to current guidelines, surgical drainage is the cornerstone of SSI treatment, and it can lead to a shorter duration of antibiotic therapy. However, in clinical practice, especially in the case of organ/cavity SSI, surgical reintervention is not always the golden rule. In this scenario, real life data are lacking, so we planned this Special Issue in order to accept new publications on epidemiology, prevention and antimicrobial chemotherapy. Moreover, submissions on sepsis, the epidemiology of surgical infections and antimicrobial resistance in COVID-19 facilitations are especially encouraged.

Guest Editors

Dr. Antonio Riccardo Buonomo

Division of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80128 Naples, Italy

Dr. Massimo Sartelli

Department of General and Emergency Surgery, Macerata Hospital, 62100 Macerata, Italy

Deadline for manuscript submissions

closed (30 September 2024)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/113926

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)